This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Barter, P. Search for Related Content Social Bookmarking                         What's this?

Review: Reconsidering the value of fibrates: lessons from the trials

HRI (The Heart Research Institute), 145 Missenden Road, Camperdown, Sydney, NSW 2050, Australia, p.barter{at}hri.org.au

Therapy with both statins and fibrates reduces the risk of coronary events. In the fibrate studies the extent of reduction is disproportionately large in people with features of the metabolic syndrome such as overweight, elevated baseline levels of plasma triglyceride and low baseline high density lipoprotein-cholesterol (HDL-c). In such people, treatment with fibrates results in a 40—50% reduction in coronary heart disease events, much greater than predicted (from the human population studies) by the joint changes in concentrations of HDL-c or low density lipoprotein-cholesterol.

Key Words: fibrates • statins • coronary heart disease • metabolic syndrome.

The British Journal of Diabetes & Vascular Disease, Vol. 3, No. 3, 162-167 (2003)
DOI: 10.1177/14746514030030030201


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?